MaxCyte To Acquire Akron
(RTTNews) - MaxCyte, Inc. (MXCT) has entered into a definitive agreement to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for total consideration of $151.8 million. At the close of the transaction, MaxCyte will pay $105.0 million in cash, subject
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.